MedTrace Logo

Beta Cell Function in (Pre) Type 1 Diabetes

NCT00800085 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-12-30

No results posted yet for this study

Summary

This study will establish criteria indicating short-term loss of beta cell mass and therefore accelerated progression towards type 1 diabetes.

Conditions

Interventions

DRUG

glucose 20%

maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals

Sponsors & Collaborators

  • AZ-VUB

    lead OTHER

Principal Investigators

  • katelijn Decochez, MD PhD · UZ Brussels

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2014-10-31
Completion
2015-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800085 on ClinicalTrials.gov